Nov 5, 2026
First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.
A large international real-world study found that a multimodal explainable AI decision support tool outperformed established biomarkers for predicting immunotherapy outcomes in non-small cell lung cancer and improved physician decision-making.